NurExone Biologic Inc. (TSX.V: NRX) (OTCQB: NRXBF) (FSE: J90) has received first place in the Healthcare category at the BOLD Awards VII Gala held March 27, 2026, in Barcelona. The award recognizes the company's leadership in exosome-based therapies for central nervous system injuries. The company was selected by a panel of global industry leaders for this honor, as detailed in the press release available at https://ibn.fm/cWtqT.
In addition to the award, NurExone announced plans to engage Investor Brand Network (IBN), subject to TSX Venture Exchange approval, to support investor awareness efforts beginning April 1, 2026. The agreement includes distribution of news and updates across more than 5,000 outlets, with a monthly fee of $6,500 under a one-year term. This initiative aims to strengthen market visibility and long-term shareholder value.
NurExone is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury. Regulatory milestones, including obtaining Orphan Drug Designation, facilitate the roadmap towards clinical trials in the U.S. and Europe. Commercially, the company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top, a U.S. subsidiary, to anchor its North American activity and growth strategy.
This recognition and the planned investor outreach underscore NurExone's progress in advancing its exosome-based therapies. The BOLD Awards honor companies that demonstrate bold innovation, and winning in the Healthcare category validates NurExone's approach to treating central nervous system injuries. The engagement with IBN will help the company communicate its milestones and strategic direction to a broader audience, potentially increasing investor interest and supporting its clinical and commercial objectives.
The implications of these developments are significant for NurExone. The award enhances the company's credibility and visibility within the biotech industry, which can attract potential partners and investors. The investor awareness campaign through IBN is designed to ensure that the company's achievements and future plans are widely disseminated, which may lead to increased trading liquidity and shareholder base expansion. For patients, the progress of ExoPTEN offers hope for effective treatments for spinal cord and optic nerve injuries, conditions that currently have limited therapeutic options.
